{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/8bff5bf6\"></iframe>","width":"100%","height":180,"duration":892,"description":"David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.\n(00:31)\n Could you please provide a little bit about yourself and your background?\n \n(01:30)\n Would you please share a brief overview of the UBA1Q assay?\n \n(02:13)\n Would you provide an overview of VEXAS syndrome?\n \n(05:30)\n When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?\n \n(06:38)\n What advantage does this assay provide over other methodologies?\n \n(10:13)\n Could you share further why diagnosis is so important for these patients?\n\n(12:40)\n Is there anything else you'd like to comment about the assay?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}